Myrtol improves post-traumatic knee osteoarthritis by regulation of reactive oxygen species, transforming growth factor β1 and apoptosis in a mouse model

LIQUN DUAN, WENZHI ZHANG, FENG ZHANG and HAIPING CAI

Department of Orthopedics, Anhui Provincial Hospital, Hefei, Anhui 230001, P.R. China

Received February 7, 2016; Accepted February 10, 2017

DOI: 10.3892/etm.2017.5367

Abstract. The present study tested whether myrtol improves post-traumatic knee osteoarthritis (PTKO) by regulating the reactive oxygen species (ROS), transforming growth factor β1 (TGF-β1) and apoptosis in a mouse model. PTKO model mice were administered with 150, 300 or 450 mg/kg myrtol for 8 weeks. ELISA analysis was used to measure tumor necrosis factor-α, interleukin-6, malondialdehyde, superoxide dismutase, reactive oxygen species and TGF-β1 levels. Caspase-3 and Bax protein expressions were analyzed using western blot analysis. In the current study, treatment with myrtol improved the tissue damage and osteoarthritis score, while it also reversed the subchondral bone thickness, subchondral bone density, trabecular bone volume/relative trabecular bone volume ratio and trabecular bone spacing in PTKO mice. The activity of tumor necrosis factor α, interleukin-6, TGF-β1, malondialdehyde, superoxide dismutase and ROS were effectively inhibited, and the protein expression of caspase-3 and Bax were clearly suppressed by treatment with myrtol in a mouse model of PTKO. In conclusion, the results demonstrated that myrtol treatment improved PTKO through the suppression of inflammation, oxidative stress, ROS, TGF-β1 and Bax/caspase-3 in mice, and myrtol may be a potential agent for clinical therapy.

Introduction

Post-traumatic knee osteoarthritis (PTKO) is a common disease presenting joint degenerative changes (1). PTKO is most frequently detected in the elderly population, with an estimated 15 million cases in China (2). Survey data in the United States also demonstrated that PTKO is the second most common cause of disability in males >50 years old, after cardiovascular disease (3). Thus, prevention and treatment of PTKO have become one of the most difficult issues in clinical practice at present (3).

Transforming growth factor β1 (TGF-β1) is a member of the TGF-β superfamily and a type of multifunctional polypeptide growth factor (4). It participates in the proliferation and differentiation processes of diversified cell types, such as chondrocytes, epithelial cells and fibroblasts, and has essential regulating effects in the developing process of embryo, organs and cartilage. Studies have demonstrated that, in the chondrocytes of rabbits and cattle, TGF-β1 can regulate the synthesis of proteoglycan (4,5). In addition, TGF-β1 has the ability to promote synthesis of type II collagen by reducing consumption of proteoglycan in order to repair the cartilage (6). Therefore, it can be seen that TGF-β1 serves an important regulatory role in the process of maintaining chondrocytes and cartilage (7).

PTKO is a chronic autoimmune disease characterized by joint synovitis, and its early lesion mainly presents on the synovial membrane (8). Synovial cells are subject to rapid proliferation due to autoimmunne response resulting from an external stimulus, such as infection or trauma (9); thus, the infiltration of diversified inflammatory cells on the synovial membrane is enhanced (9). In addition, a large number of cytokines, inflammatory proteins and various antibodies jointly mediate the inflammation-induced tissue damage in PTKO (10). During the pathological process of PTKO, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6 and other proinflammatory cytokines, as well as the inflammatory mediator prostaglandin E2 (PGE2), serve an important role (11).

Pharmacological and clinical studies in China and abroad have revealed that myrtol standardized, a natural phytomedicine used for the therapy of acute or chronic sinusitis and bronchitis, has high safety, reduced adverse reactions and good clinical efficacy (12). Furthermore, it has extensive clinical efficacy on respiratory system diseases. Domestic clinical studies have shown that its clinical efficacy is similar to the total curative effect of the import gel myrtol forte group (12). Furthermore, pharmacological and pharmacodynamics studies have demonstrated that myrtol standardized has expectorant anti-inflammatory effects, relieving cough and asthma, and reported reduced toxicity and side-effects (13).

The present study investigated whether myrtol improves PTKO through regulation of reactive oxygen species (ROS), TGF-β1 and apoptosis in mice.
Materials and methods

Animals. A total of 60 C57BL/6N female mice (20±1 g; 8-weeks-old) were obtained from Laboratory Animal Center of Anhui Medical University (Hefei, China) and divided into five cages. All mice were kept under controlled environmental conditions (temperature, 23±1°C; 50-60% relative humidity; 12 h alternate light-dark cycles). All experiments have been approved by the Ethics Committee of Anhui Provincial Hospital (Hefei, China).

PTKO model and myrtol administration. All mice were randomly divided into five groups, including the control (8 mice), PTKO (16 mice), low dose myrtol-treated (12 mice), medium dose myrtol-treated (12 mice) and high dose myrtol-treated (12 mice) groups. This loading protocol causes alendronate rupture with associated avulsion fracture from the distal femur (14). Mice were anesthetized with intraperitoneal injection of 3% sodium pentobarbital (Sigma-Aldrich, St. Louis, MO, USA), with 1 mm/sec loading rate of a single dynamic overload cycle to a target compressive load of 12 N. Knee injury in mice was performed by the release of compressive force during loading and by an audible click. Mice in the low, medium and high myrtol dose groups were administered with 150, 300 or 450 mg/kg myrtol (G.Pohl-Boskamp GmbH, Hohenlockstedt, Germany), respectively, every day for 8 weeks following knee injury. In the control group, rats were anesthetized only. The control and PTKO groups were given equal volume of saline.

Hematoxylin and eosin staining. At 8 weeks following myrtol treatment, rats were sacrificed, and knee tissue samples were acquired and fixed in 10% paraformaldehyde for 24 h at room temperature. Tissues were paraffin-embedded and stored at 4°C until required. The tissue samples from each group were then cut into 4 μm sections using a paraffin slicing machine (RM2235; Leica, Wetzlar, Germany), stained with hematoxylin and eosin, and observed under light microscopy (BH3-MJL; Olympus Corp., Tokyo, Japan). Osteoarthritis score was determined using the modified Mankin scoring system (15). Next, the synovial extension score was determined as absence (score 0) and presence (score 1) of synovial tissue outgrowth parallel to the surface of the meniscus (score 2), the meniscus adjacent to the femoral and tibial surfaces in both the anterior (score 3) and posterior regions (score 4).

Micro-computed tomography (micro-CT) analyses. Knee tissue samples were acquired, placed into 10% paraformaldehyde for 24 h and scanned using a micro-CT system (vivaCT; Scanco Medical, Basserdorf, Switzerland). The subchondral bone thickness (mm), subchondral bone density (mg hydroxyapatite/cm²), trabecular bone volume (cm³), relative trabecular bone volume (BV/TV) ratio and trabecular bone spacing (mm) were analyzed.

ELISA analysis of TNF-α, IL-6, malondialdehyde (MDA), superoxide dismutase (SOD), ROS and TGF-β1 levels. A total of 200 μl of blood was collected from mice in each group immediately following sacrifice and separated using centrifugation at 5,000 x g for 10 min at 4°C. Blood serum was acquired and analyzed for TNF-α (cat. no. E-CL-M0047c), IL-6 (cat. no. E-CL-M0042c), MDA (cat. no. E-EL-0060c), SOD (cat. no. E-EL-M2424c) and TGF-β1 (cat. no. E-EL-M0051c) levels using ELISA kits (Wuhan Huamai Biotech Co., Wuhan, China), according to the manufacturer’s instructions. ROS was measured using Reactive oxygen species Assay kit (cat. no. E004; Nanjing Jiancheng Biology Engineering Institute, Nanjing, China). Absorbance was measured using an M200 plate reader (Techan Trading AG, Mannedorf, Switzerland) at 450 nm.

Western blot analysis. Knee tissue samples were acquired and prepared in a lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). Following homogenization, the samples were centrifuged at 10,000 x g for 30 min and the protein contents were estimated with a BCA protein assay kit (Beyotime Institute of Biotechnology). Protein extraction was resolved by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and samples were then transferred onto a nitrocellulose membrane (Sigma-Aldrich). The nitrocellulose membrane was blocked with 5% bovine serum albumin or 5% non-fat dry milk. the nitrocellulose membrane was incubated with 1:5,000 anti-caspase-3 (sc-7148; 1:4,000), anti-Bax (sc-6236; 1:3,000) and β-actin (sc-130656; 1:5,000; all from Santa Cruz Biotechnology, Dallas, TX, USA) antibodies. After treatment with anti-caspase-3, membranes were subsequently washed with PBS for three times at 5 min and incubated with mouse anti-rabbit IgG-HRP (sc-2357; 1:5,000, Santa Cruz Biotechnology) for 1 h at 37°C and visualized by an enhanced chemiluminescence assay kit (KGP1125; Nanjing KeyGen Biotech. Co., Ltd., Nanjing, China). The protein expression was scanned with a densitometer and analyzed with Multi-Analysetm software 3.0 (Bio-Rad Laboratories, Inc, Hercules, CA, USA).

Statistical analysis. Results are expressed as the mean ± standard deviation. Statistically significant differences were evaluated using one-way analysis of variance with SPSS version 13.0 software (SPSS, Inc., Chicago, IL, USA), and were indicated by P<0.05.

Results

Myrtol reduces osteoarthritis in the PTKO mouse model. After treatment for 8 weeks, the extent of knee osteoarthritis in the PTKO model group was higher compared with that of the control group, as observed by hematoxylin and eosin staining (Fig. 1). Low dose myrtol treatment did not have a significant effect on knee osteoarthritis in PTKO mice (Fig. 1). However, treatment with medium or high dose of myrtol significantly reduced the knee osteoarthritis in PTKO mice (Fig. 1: P=0.0034 and P=0.0012, respectively).

Myrtol improves knee tissue score in PTKO model. The osteoarthritis and synovial extension scores of each knee tissue sample were graded in order to examine the effect of myrtol treatment on PTKO. The osteoarthritis score of the PTKO model group was significantly higher compared with that of the control group (P=0.0016), and low dose myrtol treatment had no significant effect on this score in PTKO mice (Fig. 2A).
However, treatment with medium or high dose of myrtol significantly inhibited the osteoarthritis score in PTKO mice (Fig. 2A; P=0.0066 and P=0.0049, respectively). By contrast, the synovial extension score was not significantly different in the PTKO and myrtol-treated groups in comparison with the control (Fig. 2B).

Myrtol improves the results of micro-CT analyses in the PTKO model. The subchondral bone thickness (Fig. 3A; P=0.0059), subchondral bone density (Fig. 3B; P=0.0073) and BV/TV ratio (Fig. 3C; P=0.0023) in the tissues of the PTKO model group were significantly lower when compared with those of the control group. As shown in Fig. 3D, trabecular bone spacing in the PTKO model group was higher in comparison with that of the control group (P=0.0042). Low myrtol treatment did not markedly affect these four parameters in PTKO mice (Fig. 3).

Myrtol improves the results of micro-CT analyses in the PTKO model. The subchondral bone thickness, subchondral bone density, BV/TV and trabecular bone spacing in mice are shown. **P<0.01 vs. control model group; ##P<0.01 vs. PTKO group. PTKO, post-traumatic knee osteoarthritis; LDM, low dose myrtol; MDM, medium dose myrtol; HDM, high dose myrtol; BV/TV, trabecular bone volume/relative trabecular bone volume.
respectively) and trabecular bone spacing (P=0.0047 and P=0.0031, respectively) in PTKO mice (Fig. 3A-D).

**Myrtol improves the activities of TNF-α and IL-6 in the PTKO model.** To explore the effect of myrtol on the levels of inflammation factors in the PTKO model, the activities of TNF-α and IL-6 were measured using ELISA kits. As shown in Fig. 4, the activities of TNF-α (P=0.0025) and IL-6 (P=0.0013) in the PTKO model group were significantly increased when compared with those of the control group. Treatment with medium or high dose myrtol significantly reduced the TNF-α (Fig. 4A; P=0.0054 and P=0.0048) and IL-6 (Fig. 4B; P=0.0066 and P=0.0032) activities in the PTKO mice. By contrast, TNF-α and IL-6 activities in the low dose myrtol treatment group were not evidently altered compared with the model group (Fig. 4).

**Myrtol improves the levels of MDA and SOD in the PTKO model.** To further explore the effect of myrtol on oxidative stress in the PTKO mouse model, the activities of MDA and SOD were measured using ELISA kits. As shown in Fig. 5, the activity of MDA (P=0.0031) was increased and the activity of SOD (P=0.0027) was reduced in the PTKO model group in comparison with those of the control group. Treatment with medium or high dose myrtol significantly reversed the PTKO-altered MDA (P=0.0068 and P=0.0055, respectively) and SOD (P=0.0042 and P=0.0031, respectively) activities, while low dose treatment had no significant effect in PTKO mice (Fig. 5).

**Myrtol improves the level of TGF-β1 in the PTKO model.** To examine the mechanism underlying the action of myrtol treatment in PTKO, TGF-β1 level was detected using an ELISA kit. As shown in Fig. 6, there was a significant increase in TGF-β1 level of the PTKO model group, compared with the control group (P=0.0039). In the medium and high myrtol treatment groups, the TGF-β1 activation was significantly inhibited compared with the PTKO model group (Fig. 6; P=0.0066 and P=0.0021, respectively).

**Myrtol improves the level of ROS in the PTKO model.** The effect of myrtol on PTKO-induced ROS generation was determined using an ELISA kit, in order to analyze the underlying mechanism of myrtol on PTKO. As shown in Fig. 7, the ROS level in the PTKO model group was markedly increased compared with that of the control group (P=0.0018). Treatment with medium or high dose myrtol significantly reduced the PTKO-induced ROS level in PTKO mice (Fig. 7; P=0.0083 and P=0.0041, respectively).
Myrtol improves the level of caspase-3 protein in the PTKO model. To examine the mechanism of myrtol on the apoptosis of PTKO, caspase-3 protein was measured using western blot analysis. As shown in Fig. 8, the level of caspase-3 protein in PTKO model mice was higher than that of the control group (P=0.0025). Medium or high dose myrtol significantly suppressed the PTKO-induced caspase-3 protein in PTKO mice (Fig. 8; P=0.0076 and P=0.0046, respectively).

Myrtol improves the level of Bax protein in the PTKO model. To further examine the mechanism of myrtol on apoptosis in PTKO mice, Bax protein expression was measured using western blot analysis. As shown in Fig. 9, the level of Bax protein in the PTKO model was significantly increased compared with that of the control group (P=0.0031). Medium or high dose myrtol treatment significantly suppressed the PTKO-induced Bax protein in the PTKO mice (Fig. 9; P=0.0082 and P=0.0059, respectively).

Discussion

PTKO is a frequently-occurring disease that is characterized of soft tissue injury around the joint region, which can lead to articular cartilage injury and eventually involve the entire joint, resulting in articular cartilage degeneration, fibrosis and fracture, and anabrosis (16). Knee pain, stiffness and muscular movement dysfunction are the main clinical manifestations of PTKO (17). Among them, myodynamia reduction of quadriceps femoris muscles is a characteristic manifestation of PTKO muscle dysfunction (18). In the present study, myrtol treatment significantly improved knee osteoarthritis, inhibited the osteoarthritis score, and reversed the PTKO-induced changes in subchondral bone thickness, subchondral bone density, BV/TV and trabecular bone spacing. These findings are in agreement with a previous study demonstrating that myrtol ameliorated cartilage lesions by downregulating the expression of TNF-α, IL-6 and Bax in an osteoarthritis rat model (19).

Activation of IL-1β induces damage and synovial inflammation and is an important cytokine causing articular cartilage damage (20). Activation of IL-1β promotes proliferation and differentiation of synovial cells, and disintegration of the cartilage matrix and local immune complex. Free collagen and other decomposition products stimulate the synthesis of IL-1β, which forms a vicious circle (20). Furthermore, TNF-α can synthesize PGE2 and collagenase in decomposition lesions, lead to the absorption and destruction of the bone and cartilage (11), as well as promote hyperplasia of fibroblasts. Although IL-6 cannot stimulate synovial cells, chondrocytes synthesize PGE2 and collagenase. However, IL-1β and TNF-α can induce the production of IL-6. Consequently, IL-6, as an inflammatory factor, is considered to be an amplification factor of IL-1β and TNF-α. In the current study, myrtol treatment significantly reduced the TNF-α and IL-6 activities in PTKO mice. Similarly, Beuscher et al (12) revealed that myrtol standardized inhibited inflammatory (TNF-α and IL-6) and allergic mediators.

In the cartilage of PTKO mice, expression quantity has been upregulated to a certain degree, which may initiate the self-rehabilitation of cartilage successively after the cartilage damage. Thus, upregulation of TGF-β1 gene and protein promotes downstream signal transduction and regulates the proliferation and differentiation of cartilage (6). Under the effects of specific inflammatory mediators and tumor necrosis factors, the self-rehabilitation ability of cartilage has been

![Figure 7](image7.png)

Figure 7. Myrtol improves the level of ROS in a PTKO mouse model, as determined using ELISA. *P<0.01 vs. control model group; **P<0.01 vs. PTKO group. PTKO, post-traumatic knee osteoarthritis; LDM, low dose myrtol; MDM, medium dose myrtol; HDM, high dose myrtol; ROS, reactive oxygen species.

![Figure 8](image8.png)

Figure 8. Myrtol improves the level of caspase-3 protein in the PTKO model, as observed in the (A) western blots and (B) the quantified caspase-3 protein expression. *P<0.01 vs. control model group; **P<0.01 vs. PTKO group. PTKO, post-traumatic knee osteoarthritis; LDM, low dose myrtol; MDM, medium dose myrtol; HDM, high dose myrtol.

![Figure 9](image9.png)

Figure 9. Myrtol improves the level of Bax protein in PTKO model, as observed in the (A) western blots and (B) the quantified Bax protein expression. *P<0.01 vs. control model group; **P<0.01 vs. PTKO group. PTKO, post-traumatic knee osteoarthritis; LDM, low dose myrtol; MDM, medium dose myrtol; HDM, high dose myrtol.
restricted, so that the cartilage cannot be fully repaired (6). In the present study, myrtol treatment significantly inhibited the activation of TGF-β1 level in PTKO mice. Zhao et al (13) also observed that myrtol standardized inhibited TGF-β1 expression, and suppressed the levels of TNF-α, IL-1β and IL-6 in radiation-induced lung injury.

The damage of PTKO articular cartilage and bone tissue are closely associated with abnormalities of the cell apoptosis process. Over-proliferation of synovial cells is originated from comparative deficiency of synovial cell apoptosis (21). In recent years, research has detected that the second messenger ROS is associated with PTKO damage (22). The oxidative stress caused by ROS is able to damage mitochondrial respiratory chain. Damaged mitochondria can lead to cell senescence and death. However, ROS generation has an important effect on the over-proliferation of PTKO and synovial membrane (23). Previous studies have suggested that ROS can regulate cell proliferation, differentiation, programmed cell death and aging. A small increase in ROS level promotes cell proliferation (22,24), while a moderate increase can induce cell apoptosis, and high ROS levels directly cause necrocytosis. High concentration of ROS can directly or indirectly damage the mitochondrial membrane structure, induce voltage reduction of mitochondrial membrane, and lead to mitochondrial bulging (21). Mitochondrial bulging indicates that the changes of mitochondrial membrane structure will result in loss of the ATP synthesis ability (24). In the present study, myrtol treatment significantly reduced the PTKO-induced ROS level, and reversed the PTKO-altered MDA and SOD activities in a mouse model. Similarly, Rantzsch et al (25) reported that myrtol had effective antioxidative properties in patients with chronic obstructive pulmonary disease.

Cell apoptosis occurs in various physiological and pathological processes, and is a cell death program with strict regulation of energy dependence (26). In particular, Bax is the ‘molecular switch’ initiating cell apoptosis, and serves a key function on determines cell apoptosis (27). In addition, caspase is not only an important molecule in apoptosis, but also serves as a key protease of Bax (28). Activation of the caspase decomposition specificity substrate may lead to cell apoptosis (29). The present study found that myrtol significantly suppressed PTKO-induced caspase-3 and Bax protein expression in PTKO mice. A study by Ying et al (19) also demonstrated that myrtol ameliorates cartilage lesions by downregulating the expression of Bax in an osteoarthritis rat model.

In conclusion, myrtol treatment improved knee osteoarthritis, inhibited the osteoarthritis score, and reversed the PTKO-induced changes in subchondral bone thickness, subchondral bone density, BV/TV and trabecular bone spacing in a mouse model of PTKO. Myrtol also inhibited inflammation and oxidative stress, reduced ROS and TGF-β1 levels, and suppressed caspase-3 and Bax protein expression in PTKO mice. These results indicated that myrtol improves PTKO and may be a promising drug for clinical therapy.

References


